US stock futures dip as Nvidia earnings spark little cheer
Kevin Patrick Moran, the Senior Vice President, Chief Financial Officer, and Treasurer of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), recently made a significant stock purchase. According to a recent SEC filing, Moran acquired 2,000 shares of Vanda Pharmaceuticals common stock on February 21, 2025, at a price of approximately $4.39 per share. This transaction amounted to a total value of $8,778. The purchase comes at an interesting time, as InvestingPro data shows the company maintains impressive gross profit margins of 94.31% and holds more cash than debt on its balance sheet.
Following this purchase, Moran’s direct ownership in the company increased to 355,763 shares. Additionally, there is an indirect ownership of 635 shares held by his wife. This move highlights Moran’s ongoing commitment and belief in the company’s potential. According to InvestingPro analysis, the stock appears undervalued, with analyst price targets ranging from $5 to $20. Investors often closely monitor such insider activities to gauge the confidence of company executives in their firm’s future prospects. For deeper insights into VNDA’s valuation and 6 additional ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Vanda Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -$0.08, compared to the forecasted -$0.17. The company achieved a revenue of $53.2 million, exceeding the anticipated $51.23 million. Analysts from H.C. Wainwright responded by raising the price target for Vanda to $20.00, maintaining a Buy rating, while Cantor Fitzgerald reiterated its Overweight rating with a $13.00 price target. Furthermore, Vanda Pharmaceuticals announced the development of a novel antisense oligonucleotide therapeutic, VCA-894A, targeting Charcot-Marie-Tooth disease Type 2S, which has received orphan designation from the FDA.
The company also disclosed changes in executive compensation, including adjustments to annual bonuses and base salaries, as well as the awarding of restricted stock units (RSUs). For 2025, Vanda has set its revenue guidance between $210 million and $250 million. The company anticipates revenue growth driven by its product portfolio, including Fanapt for bipolar disorder and Ponvory for multiple sclerosis. Additionally, Vanda has projected long-term revenue growth, aiming for approximately $750 million from its psychiatry products by 2030.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.